164 related articles for article (PubMed ID: 17943599)
1. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.
Kuzel TM; Li S; Eklund J; Foss F; Gascoyne R; Abramson N; Schwerkoske JF; Weller E; Horning SJ
Leuk Lymphoma; 2007 Dec; 48(12):2397-402. PubMed ID: 17943599
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
Dang NH; Hagemeister FB; Pro B; McLaughlin P; Romaguera JE; Jones D; Samuels B; Samaniego F; Younes A; Wang M; Goy A; Rodriguez MA; Walker PL; Arredondo Y; Tong AT; Fayad L
J Clin Oncol; 2004 Oct; 22(20):4095-102. PubMed ID: 15353540
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
Dang NH; Pro B; Hagemeister FB; Samaniego F; Jones D; Samuels BI; Rodriguez MA; Goy A; Romaguera JE; McLaughlin P; Tong AT; Turturro F; Walker PL; Fayad L
Br J Haematol; 2007 Feb; 136(3):439-47. PubMed ID: 17233846
[TBL] [Abstract][Full Text] [Related]
4. Denileukin diftitox.
Figgitt DP; Lamb HM; Goa KL
Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
[TBL] [Abstract][Full Text] [Related]
5. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.
Walker PL; Dang NH
Clin J Oncol Nurs; 2004 Apr; 8(2):169-74. PubMed ID: 15108419
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
[TBL] [Abstract][Full Text] [Related]
7. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
LeMaistre CF
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S37-40. PubMed ID: 11707862
[TBL] [Abstract][Full Text] [Related]
8. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
[TBL] [Abstract][Full Text] [Related]
9. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
[TBL] [Abstract][Full Text] [Related]
10. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.
Foss FM; Bacha P; Osann KE; Demierre MF; Bell T; Kuzel T
Clin Lymphoma; 2001 Mar; 1(4):298-302. PubMed ID: 11707845
[TBL] [Abstract][Full Text] [Related]
11. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.
Foss F; Demierre MF; DiVenuti G
Blood; 2005 Jul; 106(2):454-7. PubMed ID: 15811959
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
Talpur R; Duvic M
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
[TBL] [Abstract][Full Text] [Related]
13. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies.
Duvic M; Geskin L; Prince HM
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):377-84. PubMed ID: 23770157
[TBL] [Abstract][Full Text] [Related]
14. Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma.
McCann S; Akilov OE; Geskin L
Clin J Oncol Nurs; 2012 Oct; 16(5):E164-72. PubMed ID: 23022942
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma.
Duvic M; Martin AG; Olsen EA; Fivenson DP; Prince HM
Leuk Lymphoma; 2013 Mar; 54(3):514-9. PubMed ID: 22891708
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.
Frankel AE; Surendranathan A; Black JH; White A; Ganjoo K; Cripe LD
Cancer; 2006 May; 106(10):2158-64. PubMed ID: 16586495
[TBL] [Abstract][Full Text] [Related]
17. [Preclinical and clinical researches of Denileukin Diftitox (Genetical Recombination) (Remitoro
Shiiba H; Takechi A; Asakura S; Kawaguchi T; Sato M
Nihon Yakurigaku Zasshi; 2022; 157(5):376-382. PubMed ID: 36047157
[TBL] [Abstract][Full Text] [Related]
18. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas.
Kuzel TM; Rosen ST; Gordon LI; Winter J; Samuelson E; Kaul K; Roenigk HH; Nylen P; Woodworth T
Leuk Lymphoma; 1993 Nov; 11(5-6):369-77. PubMed ID: 8124209
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.
Gorgun G; Foss F
Blood; 2002 Aug; 100(4):1399-403. PubMed ID: 12149223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
